首页> 外文期刊>Peritoneal dialysis international: Journal of the International Society for Peritoneal Dialysis >Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection.
【24h】

Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection.

机译:长期使用莫匹罗星预防预防出口部位感染的慢性腹膜透析患者对莫匹罗星耐药的金黄色葡萄球菌的出现。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To determine the prevalence of the carriage of Staphylococcus aureus (SA), methicillin-resistant Staphylococcus aureus (MRSA), and mupirocin-resistant Staphylococcus aureus (MuRSA) in chronic peritoneal dialysis (CPD) patients after 4 years of prophylactic mupirocin application to the exit site, in a peritoneal dialysis unit. METHODS: Three swabs were collected from the nares, axillae/groin, and exit site, respectively, from 149 patients on CPD between May and July 2001. All swabs were cultured on solid selective agar (mannitol salt agar) and in mannitol salt broth. Staphylococcus aureus isolates were tested for methicillin resistance using oxacillin screening plates, and mupirocin resistance using E-test strips. Low-level MuRSA was defined as minimum inhibitory concentration (MIC) of 4 mg/mL or more, and high-level MuRSA as MIC of 256 mg/mL or more. RESULTS: Staphylococcus aureus was isolated from 26 (17%) patients (25 from nares/axilla/groin, and 1 from the exit site). High-level MuRSA was isolated from 4 patients (3% of the total study population; 15% of total SA isolates). No MRSA was detected. One patient with high-level MuRSA had peritonitis due to SA, resulting in treatment failure and catheter loss, soon after the swabs were collected for the study. CONCLUSION: We report the emergence of high-level MuRSA in CPD patients after a 4-year practice of continuous use of mupirocin in a small number of patients in our unit. Our results may have significant implications for the future practice of prophylactic use of mupirocin by CPD patients to prevent exit-site infection.
机译:目的:确定预防性应用多柔比星霉素4年后的慢性腹膜透析(CPD)患者中携带金黄色葡萄球菌(SA),耐甲氧西林的金黄色葡萄球菌(MRSA)和耐莫匹洛星的金黄色葡萄球菌(MuRSA)的患病率腹膜透析单元中的出口部位。方法:从2001年5月至7月,从149例CPD患者的鼻孔,腋窝/腹股沟和出口部位分别采集了3个拭子。所有拭子均在固体选择性琼脂(甘露醇盐琼脂)和甘露醇盐肉汤中培养。使用奥沙西林筛选板测试金黄色葡萄球菌分离株的甲氧西林耐药性,使用E-test试纸测试其对莫匹罗星的耐药性。低水平MuRSA被定义为最小抑制浓度(MIC)为4 mg / mL或更高,高水平MuRSA被定义为MIC为256 mg / mL或更高。结果:金黄色葡萄球菌分离自26(17%)名患者(25名来自鼻孔/腋窝/腹股沟,1名来自出口部位)。从4名患者中分离出高水平的MuRSA(占研究总数的3%;分离出的SA总数的15%)。未检测到MRSA。收集拭子用于研究后不久,一名患有高水平MuRSA的患者因SA腹膜炎,导致治疗失败和导管丢失。结论:我们报告了在我们单位的少数患者中连续使用莫匹罗星4年实践后,CPD患者出现了高水平的MuRSA。我们的结果可能对CPD患者预防性使用莫匹罗星以预防出口部位感染的未来实践具有重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号